1. Home
  2. GKOS vs WH Comparison

GKOS vs WH Comparison

Compare GKOS & WH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Glaukos Corporation

GKOS

Glaukos Corporation

HOLD

Current Price

$119.43

Market Cap

6.3B

Sector

Health Care

ML Signal

HOLD

Logo Wyndham Hotels & Resorts Inc.

WH

Wyndham Hotels & Resorts Inc.

HOLD

Current Price

$72.83

Market Cap

5.7B

ML Signal

HOLD

Company Overview

Basic Information
Metric
GKOS
WH
Founded
1998
2017
Country
United States
United States
Employees
N/A
N/A
Industry
Medical/Dental Instruments
Hotels/Resorts
Sector
Health Care
Consumer Discretionary
Exchange
Nasdaq
Nasdaq
Market Cap
6.3B
5.7B
IPO Year
2015
N/A

Fundamental Metrics

Financial Performance
Metric
GKOS
WH
Price
$119.43
$72.83
Analyst Decision
Strong Buy
Buy
Analyst Count
14
13
Target Price
$132.00
$93.85
AVG Volume (30 Days)
847.6K
1.3M
Earning Date
02-17-2026
02-18-2026
Dividend Yield
N/A
2.25%
EPS Growth
N/A
38.00
EPS
N/A
4.33
Revenue
$469,820,000.00
$1,436,000,000.00
Revenue This Year
$32.39
$5.20
Revenue Next Year
$23.05
$5.82
P/E Ratio
N/A
$16.80
Revenue Growth
30.38
3.83
52 Week Low
$73.16
$69.21
52 Week High
$161.78
$113.07

Technical Indicators

Market Signals
Indicator
GKOS
WH
Relative Strength Index (RSI) 54.11 37.35
Support Level $116.73 $72.29
Resistance Level $128.84 $81.19
Average True Range (ATR) 6.18 2.29
MACD 0.07 -0.86
Stochastic Oscillator 70.18 6.80

Price Performance

Historical Comparison
GKOS
WH

About GKOS Glaukos Corporation

Glaukos Corp is an ophthalmic pharmaceutical and medical technology company focused on developing novel, dropless therapies and commercializing associated products for the treatment of glaucoma, corneal disorders, and retinal diseases. It has commenced commercialization activities for iDose TR, a first-of-its-kind, long-duration, intracameral procedural pharmaceutical implant designed to continuously deliver glaucoma drug therapy inside the eye for extended periods of time. The company also offer commercially a proprietary bio-activated pharmaceutical therapy for the treatment of a rare corneal disorder, keratoconus. It has three primary commercialized micro-scale surgical device products designed to treat glaucoma: the iStent, the iStent inject W, and the iStent infinite.

About WH Wyndham Hotels & Resorts Inc.

As of June 30, 2025, Wyndham Hotels & Resorts operates 846,700 rooms across more than 20 brands predominantly in the economy and midscale segments. Super 8 is the largest brand, representing around 18% of all rooms, with Days Inn (13%) and Ramada (14%) the next two largest brands, as of the end of 2024. During the past several years, the company has expanded its extended stay/lifestyle brands, which appeal to travelers seeking to experience the local culture of a given location. The company closed its La Quinta acquisition in the second quarter of 2018, adding around 90,000 rooms at the time the deal closed. Wyndham launched a new extended stay economy scale segment concept, ECHO, in the spring of 2022. The United States represents 56% of total rooms, as of the end of 2024.

Share on Social Networks: